Author: BigGuy

Posted on

Judge denies emergency order to give ivermectin

A Manhattan judge says she won’t force a hospital to give an ailing post-COVID-19 patient the controversial drug ivermectin after the man’s wife sued for the non-FDA-approved treatment, according to a new ruling. Erika Quintero-Sherry brought a civil case against Mount Sinai Hospital on Jan. 26 seeking an emergency order to have the drug given to husband Benjamin Chernyavsky — who’s been “on death’s doorstep” after contracting the virus last month. Following two days of hearings in the case last week, including testimony from two Mount Sinai doctors, Manhattan Supreme Court Justice Lynn Kotler said she wouldn’t grant the emergency request to force the hospital’s staff to administer the risky drug based on Quintero-Sherry’s “paltry” evidence and going against Chernyavsky’s treating doctor’s recommendations, as well as the recommendations from the medical community at large.

Benjamin Chernyavsky
Benjamin Chernyavsky contracted the virus on Jan. 9, 2022, and was eventually placed on a ventilator.
Court documents
ivermectin
Ivermectin is not approved for the prevention or treatment of COVID-19, according to the FDA.

“Plaintiff would have this court order defendants to administer an unapproved treatment to her husband against defendants’ medical opinion rendered in the independent exercise of their professional judgment,” Kotler’s Tuesday decision reads. “Indeed, the record reveals that if prescribed ivermectin, Mr. Chernyavsky’s condition may very well worsen.” “The prevailing view in the medical community … is that ivermectin should not be prescribed,” Kotler said, noting that that is the opinion of the FDA, the Centers for Disease Control and Prevention and many other medical associations. “Plaintiff’s paltry showing is insufficient to overcome the mountain of evidence showing that ivermectin is not presently safe or effective in the treatment of COVID-19,” Kotler wrote. Kotler also noted testimony from a Mount Sinai doctor that Chernyavsky was likely no longer infected with COVID-19, but rather “now must recover from the effects the disease has had on his body and organs.” While the judge did not grant the emergency motion, the rest of the case must still play out in court. “Mount Sinai is committed to providing the highest quality care to all of our patients and uses evidence-based data in our clinical decision-making,” a hospital spokesperson said in a statement. “We are pleased with the judge’s decision to sustain the decis Quintero-Sherry’s lawyers did not immediately return a request for comment. The 60-year-old father of five contracted the virus on Jan. 9 and was eventually put into a medically induced coma and also placed on a ventilator. Quintero-Sherry argued that her husband had a less than 20 percent chance of survival. The wife also said that since the hospital had exhausted all the COVID-19 protocols for patients, rather than continuing the alleged “wait-and-see” approach, there was nothing to lose by treating her husband with ivermectin. The drug — a horse and cow de-wormer — raised headlines during the pandemic after COVID patients were reportedly using it to treat the bug.

It’s approved for human use to treat parasitic infections, head lice and some skin conditions, according to the FDA.

“The FDA has not authorized or approved ivermectin for use in preventing or treating COVID-19 in humans or animals,” the agency says on its website. ions of our clinicians to refrain from using ivermectin for treatment of COVID -19.” “Ivermectin has not been shown to be safe nor effective for the treatment or prevention of COVID-19, and the FDA has not authorized or approved this treatment for this use,” the statement continued. NN: Ivermectin a Nobel prize winning drug designated by the WHO as an essential medicine. Countless studies have shown it to be a powerful antiviral inhibiting the ACEII receptor. It has been administered in over a billion doses and is one of the safest medicines ever developed……

Posted on

Moderna eyes COVID booster by August

BRUSSELS (Reuters) – An Omicron-specific booster could be ready by August, the CEO of U.S. biotech firm Moderna told Reuters, but the firm is still gathering clinical data to determine whether that vaccine would offer better protection than a new dose of the existing jab. Last month Moderna began clinical trials for a booster dose specifically designed to target Omicron but initial results from studies in monkeys show the Omicron-specific shot may not offer stronger protection than a new dose of the existing vaccine. Moderna chief executive Stephane Bancel said in an interview the company aimed to have a booster ready by August 2022, before next autumn when he said more vulnerable people may need it. Moderna’s vaccines use mRNA technology to provoke an immune response, similar to the shot developed by Pfizer/BioNTech.

“We believe a booster will be needed. I don’t know yet if it is going to be the existing vaccine, Omicron-only, or bivalent: Omicron and existing vaccine, two mRNA in one dose.”

He said a decision would be made in the coming months when clinical data becomes available. Bancel also confirmed that under the best-case scenario Moderna would have ready by August 2023 a so-called pan-vaccine which would protect simultaneously against COVID-19, flu and other respiratory diseases. He added that pricing for this vaccine under development would be “very similar” to that applied to the current vaccine. Moderna charges different prices for different regions of the world with a range between $15 and $37, according to UNICEF, a United Nations agency involved in the distribution of vaccines to poorer nations. NN: many people are delaying their 4th shot. It is because of bogus information being spread that their will be a booster in March with new RNA targeting the latest variants. That is just not true.Try August! If your last vaccine is more than 4 months old your protection has dropped. Lets face facts we are into a 4 times a year regiment. We are averaging 3 major new variants a year, The latest wave the Omicron variant has run its course. BUT unfortunately its just not that easy. Their are several variants that are warming up in the wings. Do not get all silly on me. Another wave is coming. The messaging has been dismal. Reality is the science is evolving like science is suppose to do. The reason the messaging keeps changing is simple. Their are new mutations and we learn more every day. Its the nature of the beast.

Posted on

S. Korea: Daily virus cases at new record of 54,941 Germany: 7-day incidence rate at new record of 1474.3

SEOUL, Feb. 12, 2022 (BSS/Xinhua) – South Korea’s daily number of COVID-19 cases hit a record high amid the spread of the Omicron variant, the health
authorities said on Saturday. According to the Korea Disease Control and Prevention Agency (KDCA), the country reported 54,941 more cases of COVID-19 for the past 24 hours, raising the total number of infections to 1,294,205. The daily caseload was up from 53,926 in the previous day, hovering above 50,000 for the third consecutive day. The recent resurgence was driven by infections in the Seoul metropolitan area amid the rapid spread of the Omicron variant, which became a dominant strain here. Of the new cases, 13,189 were Seoul residents. The number of the newly infected people living in Gyeonggi province and the western port city of Incheon was 15,952 and 5,059 respectively. The virus spread also raged in the non-metropolitan region. The number of new infections in the non-capital areas was 20,628, or 37.6 percent of the total local transmission.Among the new cases, 113 were imported from overseas, lifting the total to 27,090. The number of infected people who were in a serious condition stood at 275, up four from the previous day. Thirty-three more deaths were confirmed, leaving the death toll at 7,045. The total fatality rate was 0.54 percent. The country has administered COVID-19 vaccines to 44,725,434 people, or 87.2 percent of the total population, and the number of the fully inoculated people was 44,207,093, or 86.1 percent of the population. The number of those who received booster jabs was 29,244,945 people, or 57.0 percent of the population.

Germany: 7-day incidence rate at new record of 1474.3

Germany’s seven-day incidence rate, which counts the number of people infected with COVID-19 per 100,000 inhabitants, came in at 1474.3 on Saturday, setting a new record high. The figure for new cases of the virus registered daily declined in comparison to the previous days, standing at 209,789. The tally of people that contracted the disease since the beginning of the pandemic thus rose to 12,219,501. Meanwhile, the count of deaths linked to COVID-19 went up by 198 in the previous 24 hours to 119,877.

Posted on

Israeli study offers strongest proof yet of vitamin D’s power to fight COVID

Israel scientists say they have gathered the most convincing evidence to date that increased vitamin D levels can help COVID-19 patients reduce the risk of serious illness or death.Researchers from Bar Ilan University and the Galilee Medical Center say that the vitamin has such a strong impact on disease severity that they can predict how people would fare if infected based on nothing more than their ages and vitamin D levels.

Lacking vitamin D significantly increases danger levels, they concluded in newly peer-reviewed research published Thursday in the journal PLOS One. Continue reading “Israeli study offers strongest proof yet of vitamin D’s power to fight COVID”

Posted on

Japan’s Kowa says Ivermectin showed antiviral effect

TOKYO, Jan 31 (Reuters) – Japanese trading and pharmaceuticals company Kowa Co Ltd (7807.T) on Monday said that anti-parasite drug ivermectin showed an “antiviral effect” against Omicron and other coronavirus variants in joint non-clinical research. The company, which has been working with Tokyo’s Kitasato University on testing the drug as a potential treatment for COVID-19, did not provide further details. The original Reuters story misstated that ivermectin was “effective” against Omicron in Phase III clinical trials, which are conducted in humans. Clinical trials are ongoing, but promotion of ivermectin as a COVID-19 treatment has generated controversy NN: I cannot tell you for sure Ivermectin works. I can tell you for sure it does not hurt. As I sit here taking 3 3mg capsules part of my twice a week routine. Because there is no money in a off patent it will takes years before we have “proof” Well I do not have years since mutation after wave of mutation is coming at me over and over again. So I take Ivermectin as a hedge. I am also FULLY vaccinated. wearing my ugly mask (yes I hear laughter) as day after day I hear reports of N95 toilet paper coffee filter mask user get infected. And I isolate, take my booster vitamins and test. So far only one person on staff has gotten infected and sick Mosh. And he refused to get his vaccine and wore double N95 masks even though he had our ugly masks. And within days of taking Ivermectin the infection cleared and he tested negative… So go figure…

I. Vaccinnate

2. Ivermectin

3. Quarelquinnine

4. Niclosamide

5. Booster Vitamins

Before taking any medicine or supplement consult your medical professional………

Posted on

COVID patients face risks after hospital

Reuters) – The following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that has yet to be certified by peer review. COVID-19 patients face risks after hospital discharge People face substantially higher risks of health problems in the months after being discharged from the hospital following a bout of COVID-19, researchers in England found. Comparing 24,673 COVID-19 patients who survived at least a week after hospital discharge and 123,362 similarly aged people in the general population, they found the COVID-19 survivors had twice the risk of hospital admission or death during the next 10 months. Compared with 16,058 patients who had been hospitalized for influenza, the COVID-19 patients were 37% more likely to be readmitted or die due to their initial infection or other lower respiratory tract infection, and 37% more likely to experience cognitive-related admission or death, researchers reported in PLOS Medicine. COVID-19 patients with dementia who survived hospitalization were at particularly high risk for death in the months afterward, according to the report. “Large numbers of people have been hospitalized with COVID-19… and the raised risks of death and readmission… could significantly impact public health and resources,” the researchers wrote. “Risks might be minimized or mitigated by increasing monitoring of patients in the months following hospital discharge, and greater awareness among patients and clinicians of potential problems.” When the SARS-CoV-2 spike breaks into cells via a “gateway” protein on cell surfaces called ACE2, a second cell-surface protein called vimentin facilitates the process, possibly by serving as a bridge between the virus and ACE2, new research suggests. Using sophisticated analytical chemistry techniques, the researchers observed that vimentin attaches itself to the spike protein on the surface of the coronavirus. Based on their findings, they believe it might also attach itself to the ACE2 protein. In test tube experiments, they saw that when both vimentin and ACE2 are present, entry of the virus into the cells that line the blood vessels increases. They also found that depletion of vimentin significantly reduces SARS-CoV-2 infection of human cells, according to a report published in PNAS. Study coauthor Nader Rahimi of Boston University School of Medicine said his team found that a monoclonal antibody developed by Abcam Plc blocked vimentin from binding to the virus, in turn keeping the virus from entering the cells. Vimentin is also found on cells lining the heart, the air sacs of the lungs, and the nose, the researchers noted. “Establishing the full range of the involvement of vimentin in viral entry and infection will require further investigations,” the researchers said in a statement. They said they hope their findings will lead to new antiviral drugs that keep both ACE2 and vimentin from interacting with the coronavirus. NN: As your librarian I keep coming back to Ivermectin and other antivirals like Niclosanmide which is over the counter in many places so talk to your heath professional. And of course get fully vaccinated. See the latest research from NCBI below.

Niclosamide PDF Download

Posted on

Covid-Infected HIV Patient Developed Mutations, Study Shows

https://youtu.be/rOF-4Ka_qPI

The study adds to evidence that Covid-19 may mutate rapidly when harboured by immunosuppressed individuals such as those not taking medication to treat HIV, and this may lead to the development of new variants. The Beta variant, with which the patient in the study was infected, was discovered in SA, as was the Omicron variant. “This case, like others before, describes a potential pathway for the emergence of novel variants,” the scientists said, stressing it was a hypothesis. “Our experience reinforces previous reports that effective anti-retroviral treatment is the key to controlling such events.” SA has the world’s biggest HIV epidemic with 8.2-million of its 60-million people infected with the virus which weakens the immune system. The coronavirus harboured by the patient in the study developed at least 10 mutations on the spike protein, which allows it to bind with cells, and 11 other mutations, the scientists said. Some of the changes were common to those seen in the Omicron and Lambda variants while other were consistent with mutations that allow the virus to evade antibodies.

Posted on

Omicron deaths in USA EXCEED DELTA PEAK

More signs emerged that the Omicron wave is taking a less serious human toll in Europe than earlier phases of the pandemic as U.S. data showed daily average deaths from the disease exceeding the peak reached during the surge driven by the previously dominant Delta variant. In the U.S., the seven-day average for newly reported Covid-19 deaths reached 2,258 a day on Tuesday, up about 1,000 from daily death counts two months ago, data from Johns Hopkins University show. That is the highest since February 2021 as the country was emerging from the worst of last winter’s wave. While there is a large body of evidence suggesting that Omicron is less likely to kill the people it infects, it spreads much more quickly and therefore infects many more people than earlier variants, epidemiologists say. Continue reading “Omicron deaths in USA EXCEED DELTA PEAK”

Posted on

Fourth COVID vaccine shot raises resistance to serious illness for over-60s: Israel

A fourth dose of Covid-19 vaccine given to people over 60 in Israel made them three times more resistant to serious illness than thrice-vaccinated people in the same age group, Israel’s Health Ministry said on Sunday. The ministry also said the fourth dose, or second booster, made people over 60 twice as resistant to infection than those in the age group who received three shots of the vaccine. A preliminary study published by Israel’s Sheba medical centre last Monday found that the fourth shot increases antibodies to even higher levels than the third but “probably” not to the point that it could completely fend off the highly transmissible Omicron variant. Israel began offering a fourth dose of the Pfizer/BioNtech vaccine to people over 60 earlier this month as Omicron swept the country. The ministry said on Sunday the study it conducted with several major Israeli universities and the Sheba centre compared 400,000 people over 60 who received the second booster with 600,000 people in the age group who were given a third shot more than four months ago. As elsewhere, Israel has seen Covid-19 cases spiral due to Omicron. But it has logged no deaths from the variant.
Posted on

Only one antibody treatment works against omicron — and it’s running out

As the omicron variant became the dominant strain in the U.S. this week, health care providers are left with fewer options to treat positive COVID-19 patients as most of the existing treatments have been found to be less effective in fighting off the new variant. Up until recently, the U.S. Department of Health and Human Services (HHS) had been distributing three types of COVID-19 antibody treatments, Regeneron monoclonal antibodies, Eli Lilly’s antibody treatments and GlaxoSmithKline’s sotrovimab monoclonal antibody. Regeneron gained national attention when former President Trump contracted COVID-19 and was treated with Regeneron under a “compassionate use program” that allowed rare, exceptional circumstances to use the treatment. However, as omicron emerged and scientists around the world scrambled to understand how current vaccines and available therapies could fight the new variant, Regeneron and Eli Lilly both announced their antibody treatments didn’t work as effectively in diffusing omicron. On Dec. 16, Regeneron announced its antibody treatment had “diminished potency against omicron.” In a statement to a local Fox News station, Eli Lilly confirmed that its antibody treatments showed “reduced neutralization activity,” against omicron. That leaves one COVID-19 treatment available to treat omicron infections, and in early December, GlaxoSmithKline (GSK) announced that its sotrovimab monoclonal antibody “retains in vitro activity against the full known omicron spike protein.” Meaning that GSK’s treatment could fight against all tested variants of COVID-19. It gained emergency use authorization by the U.S. Food and Drug Administration in May this year. George Scangos, CEO of Vir, the company partnering with GSK to develop sotrovimab, told The New York Times that when developing their antibody treatment they looked at the blood of people who had survived the 2003 SARS epidemic, instead of those who survived COVID-19 infections. Through this method, they identified an antibody from SARS that could also protect against the coronavirus that caused COVID-19. “I think we got here not by good luck, but by a thoughtful process,” said Scangos. However, currently health care providers are left with slimmer treatment options, as HHS data indicates that as of Dec. 17 the government had stopped distribution of Regeneron and Eli Lilly’s COVID-19 treatments and had only shipped 55,000 GSK treatments. Since mid-September, the HHS had shipped 1.2 million doses of Regeneron to states and around 670,000 doses of Eli Lilly’s antibody treatment.

According to the Times, hospitals in New York have recently said they would also stop giving patients the two most commonly used antibody treatments, made by Regeneron and Eli Lilly.

Ralph Madeb, New York Community Hospital’s co-chief medical officer said, “if I had a choice I would give GSK.” Supply of GSK’s sotrovimab monoclonal antibody is currently limited, but the White House is in discussions with the pharmaceutical company to secure more doses that could be delivered early next year, according to the Times. Along with sotrovimab, federal regulators are expected to authorize antiviral pills from pharmaceutical companies Pfizer and Merck, which would add to health care providers’ toolbelt of treatment options for COVID-19 patients.